While there are no cell or gene therapies that have been approved for the treatment of obesity, several promising therapies are being studied in clinical trials
Designed for Combination Use The CJC-1295 + Ipamorelin pairing is the most widely discussed GHRH + GHRP combination, and its selectivity is the pharmacological reason it became the default GHRP in that framework
ATTAIN-1 (NCT05869903) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes
On days when Ive had a chronic pain episode, where focus eludes me, or I didnt sleep well the night before, I curl up for a power nap and set my timer for 17 minutes